Eton Pharmaceuticals (ETON) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 revenue of $22.5 million, up 129% year-over-year and 19th consecutive quarter of sequential growth, driven by ALKINDI SPRINKLE, Carglumic Acid, INCRELEX, and GALZIN, with INCRELEX as the largest contributor.

• GALZIN launch exceeded expectations, surpassing the year-end target for active patients; ALKINDI SPRINKLE and KHINDIVI also showed strong growth, with label expansion efforts underway.

• Generated $12 million in operating cash flow and maintained disciplined expense control, reducing adjusted SG&A sequentially.

• Adjusted EBITDA reached $2.9 million, impacted by non-recurring INCRELEX ex-U.S. transition costs.

• Pipeline progress includes ET-600 NDA under FDA review (PDUFA date February 25, 2026), ET-700 extended-release development, and plans for KHINDIVI and INCRELEX label expansion.

Financial highlights

• Q3 2025 revenue was $22.5 million, up from $10.3 million in Q3 2024 (129% increase), with $0.9 million from non-recurring INCRELEX inventory sales and $2.4 million from initial INCRELEX loading order for Esteve.

• Adjusted gross profit was $10.2 million (45% margin), down from 64% prior year due to INCRELEX ex-U.S. transition costs; core U.S. business gross margin exceeded 70%.

• Adjusted EBITDA for Q3 2025 was $2.9 million, up from $2.0 million in Q3 2024; non-GAAP net income was $1.5 million.

• GAAP net loss for Q3 2025 was $1.9 million ($0.07 per diluted share), compared to net income of $0.6 million in Q3 2024.

• Ended the quarter with $37.1 million in cash and $12 million in operating cash flow.

Outlook and guidance

• Expects continued sequential U.S. product sales growth in Q4, though total product sales may be flat or slightly down due to non-recurring INCRELEX revenue.

• Fourth-quarter adjusted gross margin expected to be approximately 70%; long-term gross margin projected to exceed 75% by 2028 as product mix shifts.

• Anticipates strong revenue growth in 2026 from core products and new launches, with more detailed guidance to be provided with Q4 results.

• Management expects current cash and product revenues to fund operations for at least the next twelve months; additional financing may be needed if growth or spending outpaces projections.

• ET-600 launch expected in Q1 2026, pending FDA approval; plans to initiate ET-700 and KHINDIVI studies in early 2026.